Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Corcept Therapeutics Inc (NASDAQ: CORT) was $71.38 for the day, up 2.38% from the previous closing price of $69.72. In other words, the price has increased by $2.38 from its previous closing price. On the day, 0.81 million shares were traded. CORT stock price reached its highest trading level at $71.614 during the session, while it also had its lowest trading level at $69.33.
Ratios:
Our analysis of CORT’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 41.72. For the most recent quarter (mrq), Quick Ratio is recorded 2.98 and its Current Ratio is at 3.06. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on November 06, 2023, Upgraded its rating to Buy and sets its target price to $38 from $29 previously.
On April 11, 2023, SVB Securities started tracking the stock assigning a Market Perform rating and target price of $25. On April 04, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on April 04, 2023, with a $27 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 02 ’25 when Guyer William bought 20,000 shares for $69.72 per share.
Maduck Sean bought 20,000 shares of CORT for $1,394,400 on Sep 02 ’25. On Sep 02 ’25, another insider, Lyon Joseph Douglas, who serves as the Officer of the company, bought 5,000 shares for $69.72 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 7521453056 and an Enterprise Value of 7185812992. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 63.52, and their Forward P/E ratio for the next fiscal year is 32.74. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.99. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.50 while its Price-to-Book (P/B) ratio in mrq is 11.82. Its current Enterprise Value per Revenue stands at 10.035 whereas that against EBITDA is 70.023.
Stock Price History:
The Beta on a monthly basis for CORT is 0.29, which has changed by 1.0618141 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, CORT has reached a high of $117.33, while it has fallen to a 52-week low of $33.34. The 50-Day Moving Average of the stock is 0.58%, while the 200-Day Moving Average is calculated to be 8.59%.
Shares Statistics:
CORT traded an average of 1.18M shares per day over the past three months and 653130 shares per day over the past ten days. A total of 105.29M shares are outstanding, with a floating share count of 93.24M. Insiders hold about 11.51% of the company’s shares, while institutions hold 75.41% stake in the company. Shares short for CORT as of 1755216000 were 10590834 with a Short Ratio of 9.01, compared to 1752537600 on 11223626. Therefore, it implies a Short% of Shares Outstanding of 10590834 and a Short% of Float of 13.58.
Earnings Estimates
Current recommendations for the stock of the company come from 4.0 analysts. The consensus estimate for the next quarter is $0.44, with high estimates of $0.71 and low estimates of $0.31.
Analysts are recommending an EPS of between $1.38 and $0.8 for the fiscal current year, implying an average EPS of $1.08. EPS for the following year is $2.18, with 4.0 analysts recommending between $3.31 and $0.77.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $240M to a low estimate of $210.12M. As of the current estimate, Corcept Therapeutics Inc’s year-ago sales were $182.55MFor the next quarter, 4 analysts are estimating revenue of $289.05M. There is a high estimate of $313.23M for the next quarter, whereas the lowest estimate is $275.9M.
A total of 4 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $875M, while the lowest revenue estimate was $852.5M, resulting in an average revenue estimate of $864.45M. In the same quarter a year ago, actual revenue was $675.04MBased on 4 analysts’ estimates, the company’s revenue will be $1.19B in the next fiscal year. The high estimate is $1.38B and the low estimate is $1.01B.
